Sandoz reports year-to-date sales for the first nine months of 2023 Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Nine-month net sales1 of USD 7.1 billion, up 6 percent in constant currencies (cc)(1)Solid performance in Generics;...

Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines Spin-off from Novartis successfully completed with first trading day today on SIX Swiss Exchange; Sandoz shares included in key market indicesStandalone Sandoz committed to extend leadership in stable...